SpaceOAR System RWS in China
Primary Purpose
Localized T1-T2 Prostate Cancer
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
SpaceOAR Treatment
Sponsored by

About this trial
This is an interventional treatment trial for Localized T1-T2 Prostate Cancer
Eligibility Criteria
Inclusion Criteria:
- Subjects has provided the written informed consent, willing to participate in clinical data collection and willing to receive visit at 30 days post procedure. (for subjects enrolled prospectively)
- Subjects must have been pathologically confirmed prostate cancer with clinical stage T1-T2, and have been treated or will be treated with Space OAR Hydrogel in hospital in Hainan Boao Lecheng medical pilot zone.
Exclusion Criteria- no specific exclusion criteria unless the patients refuse to sign the informed consent.
Sites / Locations
- Boao First Life Care Center-Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
SpaceOAR Treatment Arm
Arm Description
Single arm, up to 20 subjects with a pathologically confirmed diagnosis of clinical stage T1 or T2 prostate cancer indicated for radiotherapy will be enrolled, for there are chances of missing data in the real world study. A sample of 14 subjects provides at least 90% power for the primary objective.
Outcomes
Primary Outcome Measures
Primary Effectiveness Endpoint
The distance between the posterior prostatic capsule and anterior rectal wall post SpaceOAR hydrogel administration.
Measurement: The distance between the posterior prostatic capsule and anterior rectal wall is measured on the axial image slice closest to halfway between apex and base, from posterior edge of prostate to inner rectal wall via MRI.
Primary Safety Endpoint
AEs related to SpaceOAR system and/or procedure within 30 days following procedure will be observed.
Secondary Outcome Measures
Functional Success
Defined as creation of at least 7.5mm space between the posterior prostatic capsule and anterior rectum wall as assessed via comparative pre and post SpaceOAR hydrogel injection MRI scans.
Full Information
NCT ID
NCT05407714
First Posted
May 27, 2022
Last Updated
September 26, 2023
Sponsor
Boston Scientific Corporation
1. Study Identification
Unique Protocol Identification Number
NCT05407714
Brief Title
SpaceOAR System RWS in China
Official Title
A Real Word Study to Evaluate the Safety and Performance of SpaceOAR System When Used to Create Space Between the Rectum and Prostate in Men Undergoing Radiotherapy for Localized T1-T2 Prostate Cancer in China
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
August 18, 2022 (Actual)
Primary Completion Date
June 12, 2023 (Actual)
Study Completion Date
July 6, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boston Scientific Corporation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study aims to evaluate the safety and performance of SpaceOAR System when it is used to create space between the rectum and prostate in men undergoing radiotherapy for localized T1-T2 prostate cancer in China via collecting the real word data of SpaceOAR System used, to generate local clinical evidence on Chinese patients.
Detailed Description
This study is a retrospective and prospective, single arm, real world study. For those patients who have already received the SpaceOAR treatment before study kick-off, the data at baseline and the day of procedure will be retrospectively collected. For those patients who will receive SpaceOAR treatment after study kick-off, the clinical data at baseline, the day of procedure and 30 days post procedure will be prospectively collected.
Up to 20 subjects with a pathologically confirmed diagnosis of clinical stage T1 or T2 prostate cancer indicated for radiotherapy will be enrolled, for there are chances of missing data in the real world study. A sample of 14 subjects provides at least 90% power for the primary objective.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Localized T1-T2 Prostate Cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Actual)
8. Arms, Groups, and Interventions
Arm Title
SpaceOAR Treatment Arm
Arm Type
Experimental
Arm Description
Single arm, up to 20 subjects with a pathologically confirmed diagnosis of clinical stage T1 or T2 prostate cancer indicated for radiotherapy will be enrolled, for there are chances of missing data in the real world study. A sample of 14 subjects provides at least 90% power for the primary objective.
Intervention Type
Device
Intervention Name(s)
SpaceOAR Treatment
Intervention Description
SpaceOAR System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR System to reduce the radiation dose delivered to the anterior rectum.
The SpaceOAR System is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time.
Primary Outcome Measure Information:
Title
Primary Effectiveness Endpoint
Description
The distance between the posterior prostatic capsule and anterior rectal wall post SpaceOAR hydrogel administration.
Measurement: The distance between the posterior prostatic capsule and anterior rectal wall is measured on the axial image slice closest to halfway between apex and base, from posterior edge of prostate to inner rectal wall via MRI.
Time Frame
Within 10 days post spaceOAR hydrogel administration.
Title
Primary Safety Endpoint
Description
AEs related to SpaceOAR system and/or procedure within 30 days following procedure will be observed.
Time Frame
Within 30 days following procedure
Secondary Outcome Measure Information:
Title
Functional Success
Description
Defined as creation of at least 7.5mm space between the posterior prostatic capsule and anterior rectum wall as assessed via comparative pre and post SpaceOAR hydrogel injection MRI scans.
Time Frame
Within 10 days post spaceOAR hydrogel administration.
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects has provided the written informed consent, willing to participate in clinical data collection and willing to receive visit at 30 days post procedure. (for subjects enrolled prospectively)
Subjects must have been pathologically confirmed prostate cancer with clinical stage T1-T2, and have been treated or will be treated with Space OAR Hydrogel in hospital in Hainan Boao Lecheng medical pilot zone.
Exclusion Criteria- no specific exclusion criteria unless the patients refuse to sign the informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sujun Han
Organizational Affiliation
Boao Yiling Life Care Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Boao First Life Care Center-Hospital
City
Qionghai
State/Province
Hainan
ZIP/Postal Code
571434
Country
China
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
SpaceOAR System RWS in China
We'll reach out to this number within 24 hrs